We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

173 hedge funds and large institutions have $783M invested in Nurix Therapeutics in 2025 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 49 increasing their positions, 60 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

981% more call options, than puts

Call options by funds: $1.12M | Put options by funds: $104K

42% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 24

6% more funds holding

Funds holding: 163 → 173 (+10)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4.96% less ownership

Funds ownership: 115.85% → 110.89% (-5%)

18% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 60

22% less capital invested

Capital invested by funds: $1.01B → $783M (-$223M)

Holders
173
Holders Change
+10
Holders Change %
+6.13%
% of All Funds
2.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
34
Increased
49
Reduced
60
Closed
24
Calls
$1.12M
Puts
$104K
Net Calls
+$1.02M
Net Calls Change
-$528K

Top Buyers

1
VPC
Vestal Point Capital
New York
+$15.3M
2
Deutsche Bank
Deutsche Bank
Germany
+$11.1M
3
KCM
Kynam Capital Management
New Jersey
+$10.3M
4
Millennium Management
Millennium Management
New York
+$6.19M
5
AG
Algert Global
California
+$4.67M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$20.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$16.1M
3
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$13.3M
4
UBS Group
UBS Group
Switzerland
-$12.7M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$12.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$82.1M -$16.1M -1,554,930 -15%
BlackRock
2
BlackRock
New York
$62.5M -$479K -46,112 -0.7%
DTC
3
Deep Track Capital
Connecticut
$56M -$81.9K -7,886 -0.1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$41.5M +$242K +23,269 +0.5%
BBA
5
Baker Bros. Advisors
New York
$35.9M – – –
CC
6
Commodore Capital
New York
$34.9M -$1.75M -168,598 -4%
RG
7
Redmile Group
California
$34M -$566K -54,494 -1%
VPC
8
Vestal Point Capital
New York
$32.1M +$15.3M +1,475,000 +74%
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$26.5M -$8.64M -832,097 -22%
State Street
10
State Street
Massachusetts
$26.4M +$3.43M +330,233 +13%
SCM
11
Soleus Capital Management
Connecticut
$22.4M – – –
Morgan Stanley
12
Morgan Stanley
New York
$20.9M +$972K +93,625 +4%
KCM
13
Kynam Capital Management
New Jersey
$20M +$10.3M +995,000 +85%
Pictet Asset Management
14
Pictet Asset Management
Switzerland
$18.3M -$188K -18,094 -0.9%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$17.4M +$7.5K +722 +0%
Sumitomo Mitsui Trust Group
16
Sumitomo Mitsui Trust Group
Japan
$14.4M +$1.72M +165,841 +12%
NAMA
17
Nikko Asset Management Americas
New York
$14.4M +$1.75M +168,205 +12%
Millennium Management
18
Millennium Management
New York
$14.1M +$6.19M +596,401 +64%
AIM
19
ARK Investment Management
Florida
$14M -$671K -64,628 -4%
Deutsche Bank
20
Deutsche Bank
Germany
$13.3M +$11.1M +1,069,981 +290%
PA
21
Perceptive Advisors
New York
$13.1M +$3.31M +319,164 +29%
T. Rowe Price Investment Management
22
T. Rowe Price Investment Management
Maryland
$11.1M -$13.3M -1,276,541 -52%
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$10.2M -$20.1M -1,934,751 -64%
AAA
24
Affinity Asset Advisors
New York
$8.94M – – –
Charles Schwab
25
Charles Schwab
California
$7.99M +$2.67M +257,253 +42%
1
2 3 4 5

NRIX Hedge Fund Activity: Q3 2025 in Review

173 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2025, worth a combined $783M — down 22% from $1.01B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new NRIX positions and 24 closed out — a net gain of 10 holders — while 49 added to existing stakes and 60 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $15.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $20.1M.

  • 173 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2025, up from 163 in Q2 2025.
  • Funds reported $783M of Nurix Therapeutics stock for Q3 2025, down 22% quarter-over-quarter.
  • 34 funds opened new Nurix Therapeutics positions in Q3 2025 and 24 closed out, a net change of +10 holders.
  • The largest Nurix Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $15.3M added.
  • The largest Nurix Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $20.1M sold.

Based on aggregated 13F filings for Q3 2025.